CVS Health price target raised to $89 from $82 at Morgan Stanley

Morgan Stanley analyst Erin Wright raised the firm’s price target on CVS Health (CVS) to $89 from $82 and keeps an Overweight rating on the shares. Last week’s Stars results were “encouraging” for the sector and Managed Care Organization sentiment has “improved slightly,” but there is “still a lot to prove” as the focus turns to utilization and early reads on 2026, the analyst tells investors in a Q3 earnings preview for the group.

Elevate Your Investing Strategy:

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on CVS:

Disclaimer & DisclosureReport an Issue

CVS Health initiated with a Buy at Goldman Sachs Positive Outlook for CVS Health Amid Minor Challenges: Buy Rating Affirmed CVS Health price target raised to $88 from $76 at Mizuho Amazon (AMZN) Pharmacy Brings Prescription Kiosks to Doctors’ Offices CVS Health price target raised to $103 from $84 at Wells Fargo

View Comments